MAP4K

MAPK Kinase Kinase Kinase

MAP kinase kinase kinase kinases (MAP4Ks) belong to the mammalian Ste20-like family of serine/threonine kinases. MAP4Ks including MAP4K1/HPK1, MAP4K2/GCK, MAP4K3/GLK, MAP4K4/HGK, MAP4K5/KHS, and MAP4K6/MINK have been reported to induce JNK activation through activating the MAP3K-MAP2K cascade. MAP4Ks play important roles in the regulation of cell apoptosis, cell survival, cell autophagy, and cell migration. Several studies reported that MAP4Ks are involved in the regulation of immune-cell responses through JNK-independent pathways.

MAP4K1/HPK1 and MAP4K4/HGK play negative roles in T-cell activation and inflammatory responses. In contrast, MAP4K3/GLK plays a positive role in T-cell activation and autoimmune responses. Moreover, MAP4K1 downregulation and MAP4K3 overexpression in T cells are involved in human autoimmune diseases such as psoriatic arthritis, rheumatoid arthritis (RA), adult-onset Still's disease, and SLE.

MAP4K Inhibitors

DMX-5804

Cat. No.: HY-111754

DMX-5804 is a potent, orally active and selective **MAP4K4** inhibitor, with an IC_{50} of 3 nM, a pIC_{50} of 8.55 for human MAP4K4, less potent on MINK1/MAP4K6 (pIC_{50}, 8.18), and TNIK/MAP4K7 (pIC_{50}, 7.96).



Purity: 99.63%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GNE 220

Cat. No.: HY-U00428

GNE-220 is a potent and selective inhibitor of **MAP4K4** with an IC_{50} of 7 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GNE 220 hydrochloride

Cat. No.: HY-U00428A

GNE 220 (hydrochloride) is a potent and selective inhibitor of **MAP4K4**, with an IC_{50} of 7 nM.



Purity: 98.33%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

GNE-1858

Cat. No.: HY-135892

GNE-1858 is a potent and ATP-competitive **hematopoietic progenitor kinase-1 (HPK1)** inhibitor, with IC_{50}s of 1.9 nM, 1.9 nM, and 4.5 nM for wild-type and the active mimetic mutants HPK1-TSEE and HPK1-SA, respectively.



Purity: 99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GNE-495

Cat. No.: HY-100343

GNE-495 is a potent and selective **MAP4K4** inhibitor with an IC_{50} of 3.7 nM.



Purity: 99.68%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

HPK1-IN-10

Cat. No.: HY-145036

HPK1-IN-10 is potent inhibitor of **HPK1**. HPK1 is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HPK1-IN-11

Cat. No.: HY-145037

HPK1-IN-11 is potent inhibitor of **HPK1**. HPK1 is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HPK1-IN-12

Cat. No.: HY-145038

HPK1-IN-12 is potent inhibitor of **HPK1**. HPK1 is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HPK1-IN-13

Cat. No.: HY-145039

HPK1-IN-13 is potent inhibitor of **HPK1**. HPK1 is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HPK1-IN-14

Cat. No.: HY-145040

HPK1-IN-14 is potent inhibitor of **HPK1**. HPK1 is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HPK1-IN-15

Cat. No.: HY-145041

HPK1-IN-15 is a potent and selective inhibitor of **HPK1**. Hematopoietic progenitor kinase 1 (HPKl) originally cloned from hematopoietic progenitor cells is a member of MAP kinase kinase kinase kinases (MAP4Ks) family.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HPK1-IN-16

Cat. No.: HY-145042

HPK1-IN-16 is a potent and selective inhibitor of **HPK1**. Hematopoietic progenitor kinase 1 (HPKl) originally cloned from hematopoietic progenitor cells is a member of MAP kinase kinase kinase kinases (MAP4Ks) family.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HPK1-IN-17

Cat. No.: HY-145044

HPK1-IN-17 is a potent and selective inhibitor of **HPK1**. Hematopoietic progenitor kinase 1 (HPKl) originally cloned from hematopoietic progenitor cells is a member of MAP kinase kinase kinase kinases (MAP4Ks) family.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HPK1-IN-18

Cat. No.: HY-145045

HPK1-IN-18 is a potent and selective inhibitor of **HPK1**. Hematopoietic progenitor kinase 1 (HPKl) originally cloned from hematopoietic progenitor cells is a member of MAP kinase kinase kinase kinases (MAP4Ks) family.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HPK1-IN-19

Cat. No.: HY-145107

HPK1-IN-19 is a **hematopoietic progenitor kinase 1 (HPK1)** inhibitor extracted from patent WO2018102366A1 compound I-47.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HPK1-IN-20

Cat. No.: HY-145109

HPK1-IN-19 is a **hematopoietic progenitor kinase 1 (HPK1)** inhibitor extracted from patent WO2020235902A1 compound 106.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HPK1-IN-21

Cat. No.: HY-144073

HPK1-IN-21 is a potent inhibitor of **HPK1** kinase inhibitor (**Ki**=0.8 nM), HPK1-IN-21 also has orally active.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HPK1-IN-24

Cat. No.: HY-144091

HPK1-IN-24 (example 51) is a **hematopoietic progenitor kinase 1 (HPK1)** inhibitor with a K_i of 100 nM. HPK1-IN-24 has the potential&nbs p;for cancer research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HPK1-IN-25

Cat. No.: HY-144092

HPK1-IN-25 (example 94) is a **hematopoietic progenitor kinase 1 (HPK1)** inhibitor with a enzymatic activity IC_{50} of 129 nM. HPK1-IN-25 has the potential for&nb sp;cancer research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HPK1-IN-26

Cat. No.: HY-144093

HPK1-IN-26 is a **HPK1** and **GLK** inhibitor extracted from patent WO2021254118A1 compound 1. HPK1-IN-26 can be used for the research of animal pathogen infection.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HPK1-IN-27

Cat. No.: HY-143868

HPK1-IN-27 is a potent inhibitor of **HPK1**. MAP4K1 is also known as hematopoietic progenitor kinase 1 (HPK1). MAP4K1 is a serine/threonine kinase and member of the germinal center kinase family.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HPK1-IN-28

Cat. No.: HY-143869

HPK1-IN-28 is a potent inhibitor of **HPK1**. Hematopoietic progenitor kinase 1 (HPK1) is a negative regulator of the activation response of dendritic cells (DCs), T cells and B cells. HPK1-IN-28 enhances the body's anti-tumor immunity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HPK1-IN-29

Cat. No.: HY-143870

HPK1-IN-29 is a potent inhibitor of **HPK1**. Hematopoietic progenitor kinase 1 (HPK1) is a negative regulator of the activation response of dendritic cells (DCs), T cells and B cells. HPK1-IN-29 enhances the body's anti-tumor immunity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HPK1-IN-3

Cat. No.: HY-138568

HPK1-IN-3 is a potent and selective ATP-competitive **hematopoietic progenitor kinase 1 (HPK1; MAP4K1)** inhibitor with an IC_{50} of 0.25 nM. HPK1-IN-3 has IL-2 cellular potency with an EC_{50} of 108 nM in human peripheral blood mononuclear cells (PBMCs).



Purity: 98.53%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

HPK1-IN-30

Cat. No.: HY-143871

HPK1-IN-30 is a potent inhibitor of **HPK1**. MAP4K1 is also known as hematopoietic progenitor kinase 1 (HPK1). MAP4K1 is a serine/threonine kinase and member of the germinal center kinase family.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HPK1-IN-4

Cat. No.: HY-138569

HPK1-IN-4 (comp 22) is a **HPK1 (MAPK41)** inhibitor (IC_{50} of 0.061 nM) as preclinical immunotherapy tool compound.



Purity: 99.09%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

HPK1-IN-7

Cat. No.: HY-138742

HPK1-IN-7 is a potent, orally active **HPK1** (hematopoietic progenitor kinase 1, MAP4K1) inhibitor (IC_{50}=2.6 nM) with excellent family and kinome selectivity. HPK1-IN-7 shows selectivity against IRAK4 (59 nM) and GLK (140 nM).



Purity: 99.61%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

HPK1-IN-8

Cat. No.: HY-132926

HPK1-IN-8 is an allosteric, inactive conformation-selective inhibitor of full-length **HPK1**.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

HPK1-IN-9

Cat. No.: HY-145035

HPK1-IN-9 is potent inhibitor of **HPK1**. HPK1 is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KY-05009

Cat. No.: HY-124745

KY-05009 is an ATP-competitive **Traf2- and Nck-interacting kinase (TNIK)** inhibitor with a K_i of 100 nM. KY-05009 pharmacologically inhibits TGF-β1-induced epithelial-to-mesenchymal transition (EMT) in human lung adenocarcinoma cells.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 25 mg, 100 mg

MAP4K4-IN-3

Cat. No.: HY-125012

MAP4K4-IN-3 (Compound 17) is a potent and selective **MAP4K4** inhibitor with an IC_{50} of 14.9 nM in kinase assay, an IC_{50} of 470 nM in cell assay. Antidiabetic agent.



Purity: 99.13%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NCB-0846

Cat. No.: HY-100830

NCB-0846 is an orally available **TNIK** inhibitor with an IC_{50} of 21nM.



Purity: 99.36%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NG25

Cat. No.: HY-15434

NG25 is a potent dual **TAK1** and **MAP4K2** inhibitor, with IC_{50}s of 149 nM and 21.7 nM, respectively.



Purity: 99.35%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

PF-06260933

Cat. No.: HY-19562

PF-06260933 is an orally active and highly selective inhibitor of **MAP4K4** with IC_{50}s of 3.7 and 160 nM for kinase and cell, respectively.



Purity: 98.41%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TAK1/MAP4K2 inhibitor 1

Cat. No.: HY-77251

TAK1/MAP4K2 inhibitor 1 is a potent dual TGFβ-activated kinase 1 (**TAK1**) and mitogen-activated protein kinase kinase kinase kinase 2 (**MAP4K2**) inhibitor, with IC_{50}s of 41.1 nM and 18.2 nM, respectively.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

ZYF0033

(HPK1-IN-22)

Cat. No.: HY-144088

HPK1-IN-22 (compound ZYF0033) is a **hematopoietic progenitor kinase 1 (HPK1)** inhibitor with an IC_{50} less than 10 nM based on the phosphorylation inhibition of MBP protein. HPK1-IN-22 decreases the phosphorylation of SLP76 (serine 376).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg